Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Acne Vulgaris

ClinicalTrials.gov lists 776 trials for Acne Vulgaris or a narrower condition beneath it. Galderma R&D has the most among industry and government lead sponsors, with 45.

MeSH D000152 Skin and Connective Tissue Diseases C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 93 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 106 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 127 Phase 4 Phase 4 118 Not applicable Not applicable 200 Observational Observational 97 Phase 1 Phase 1 93 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 106 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 127 Phase 4 Phase 4 118 Not applicable Not applicable 200 Observational Observational 97

Trials per phase (log scale)

775 of the 776 trials are tagged with Acne Vulgaris itself; the rest are tagged with a narrower condition beneath it.

Get the Acne Vulgaris report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Acne Vulgaris trials start? (26)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 48

2000: 1 trials (Phase 2 1) 2002: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2003: 4 trials (Phase 3 2, Phase 2/3 1, Phase 2 1) 2004: 10 trials (Observational 1, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1 1) 2005: 12 trials (Observational 1, Not applicable 2, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2006: 15 trials (Not applicable 3, Phase 4 6, Phase 3 4, Phase 2 2) 2007: 18 trials (Not applicable 2, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2008: 32 trials (Observational 2, Not applicable 6, Phase 4 8, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1 3) 2009: 42 trials (Observational 2, Not applicable 7, Phase 4 16, Phase 3 11, Phase 2 3, Phase 1 3) 2010: 33 trials (Observational 1, Not applicable 7, Phase 4 7, Phase 3 1, Phase 2 8, Phase 1/2 2, Phase 1 7) 2011: 33 trials (Observational 2, Not applicable 5, Phase 4 5, Phase 3 6, Phase 2 8, Phase 1/2 2, Phase 1 5) 2012: 31 trials (Observational 3, Not applicable 7, Phase 4 1, Phase 3 6, Phase 2 6, Phase 1/2 1, Phase 1 7) 2013: 33 trials (Observational 4, Not applicable 3, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 8) 2014: 32 trials (Observational 2, Not applicable 7, Phase 4 3, Phase 3 6, Phase 2 5, Phase 1/2 1, Phase 1 8) 2015: 46 trials (Observational 6, Not applicable 1, Phase 4 6, Phase 3 13, Phase 2 10, Phase 1/2 4, Phase 1 6) 2016: 47 trials (Observational 1, Not applicable 7, Phase 4 9, Phase 3 11, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 6) 2017: 30 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 9, Phase 2 6, Phase 1 3) 2018: 39 trials (Observational 9, Not applicable 6, Phase 4 6, Phase 3 10, Phase 2/3 1, Phase 2 3, Phase 1 4) 2019: 31 trials (Observational 5, Not applicable 8, Phase 4 3, Phase 3 2, Phase 2 5, Phase 1/2 2, Phase 1 6) 2020: 39 trials (Observational 8, Not applicable 19, Phase 4 4, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 2) 2021: 43 trials (Observational 10, Not applicable 13, Phase 4 7, Phase 3 3, Phase 2 4, Phase 1 6) 2022: 32 trials (Observational 4, Not applicable 16, Phase 4 5, Phase 3 1, Phase 2 4, Phase 1 2) 2023: 48 trials (Observational 10, Not applicable 26, Phase 4 6, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2024: 48 trials (Observational 7, Not applicable 20, Phase 4 2, Phase 3 8, Phase 2/3 2, Phase 2 1, Phase 1/2 3, Phase 1 5) 2025: 36 trials (Observational 6, Not applicable 15, Phase 4 3, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 35
2025 36
2024 48
2023 48
2022 32
2021 43
2020 39
2019 31
2018 39
2017 30

Showing 10 of 26 earlier years.

Start your 14-day trial Email me all 26 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 44 trials starting in 2026 and about 41 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 23 months from start to primary completion across 28 trials still running at the 2026-10-09 snapshot; registered median of 9 months across 570 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Acne Vulgaris trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 93
Phase 1/2 26
Phase 2 106
Phase 2/3 9
Phase 3 127
Phase 4 118
Not applicable 200
Observational 97

How many Acne Vulgaris trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 34
Recruiting 32
Enrolling by invitation 1
Active, not recruiting 14
Completed 554

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Acne Vulgaris trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Galderma R&D 45
Stiefel, a GSK Company 29
Bausch Health Americas, Inc. 27
Sun Pharmaceutical Industries, Inc. 22
Cosmetique Active International 13

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Acne Vulgaris? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Adapalene 14
DOXY 11
Benzoyl Peroxide 11
Tazarotene 6

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
CIP-Isotretinoin 28
Vehicle Gel 18
Vehicle Cream 11
Clindamycin Gel 10
Vehicle Foam 9

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Acne Vulgaris trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
HIDRADENITIS 43 3
Appendicitis 16 14
Depression 16 13
Abortion spontaneous 10 8
Suicide attempt 9 9

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Acne Vulgaris? (549)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Challenges in designing a randomized, double-blind noninferiority trial for treatment of acne: The SD-ACNE trial. Clinical trials (London, England) 2025 Yes
Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis. The British journal of dermatology 2025 Yes
Dual-Plane Treatment With Highly Concentrated Hybrid Cooperative Complexes of Hyaluronans for Facial Atrophic Acne Scars. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2025 Yes
Low-Energy Delicate Pulsed Light Therapy for Sensitive Skin: A Retrospective Study. Journal of cosmetic dermatology 2025 Yes
Performance and Safety of the Medical Device Ialuxid Gel in the Treatment of Mild-Moderate Acne Vulgaris: An Open-Label, Noncomparative Multicentre Interventional Clinical Trial. Journal of cosmetic dermatology 2025 Yes

Showing 5 of 549 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages